Crossref
Pharmacometrics insights into major bleeding risk in rivaroxaban-treated atrial fibrillation patients
International Journal of Cardiology · 2026-07 · 455 · 134331
DOI: 10.1016/j.ijcard.2026.134331 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cardiology, 2026-07. Verfasst von W.T. Tang und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Tang, W., Yong, D., Ghadzi, S. S., Harun, S., & Rosman, A. (2026). Pharmacometrics insights into major bleeding risk in rivaroxaban-treated atrial fibrillation patients. International Journal of Cardiology, 455, 134331. https://doi.org/10.1016/j.ijcard.2026.134331
Vancouver
Tang W, Yong D, Ghadzi SS, Harun S, Rosman A. Pharmacometrics insights into major bleeding risk in rivaroxaban-treated atrial fibrillation patients. International Journal of Cardiology. 2026;455:134331. doi:10.1016/j.ijcard.2026.134331
BibTeX
@article{Tang2026,
author = {Tang, W.T. and Yong, D.T.W. and Ghadzi, S.M. Sheikh and Harun, S.N. and Rosman, A.},
title = {Pharmacometrics insights into major bleeding risk in rivaroxaban-treated atrial fibrillation patients},
journal = {International Journal of Cardiology},
year = {2026},
volume = {455},
pages = {134331},
doi = {10.1016/j.ijcard.2026.134331}
}
EUVIMED